Browse recruiting and upcoming clinical trials for large granular lymphocytic leukemia.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this listHide
ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
Who can join AIAdults (18+) with T‑cell large granular lymphocytic leukemia (T‑LGLL) who need treatment, including untreated patients or those who have failed frontline therapy.
What is being studied AITests ruxolitinib to see if it induces responses and assesses safety in T-LGLL.
Who can join AIAdults with mycosis fungoides or Sézary syndrome (stages IB–IVB) or adults who require treatment for T‑cell large granular lymphocytic leukemia.
What is being studied AITests golidocitinib 150 mg daily as a treatment for two T‑cell cancers.
Who can join AIPeople diagnosed with certain hematological (blood) diseases or who received a bone marrow transplant at a participating hospital on or after January 1, 2020.
What is being studied AICollects clinical, treatment, outcome, and cost data for people with hematological diseases.
Who can join AIPeople being evaluated for a hematologic cancer or related blood or lymphoid disorder (leukemia, lymphoma, multiple myeloma, myelodysplastic and myeloproliferative disorders, and related neoplasms) at the University of North Carolina Hospitals — in the hematology/oncology clinics, the stem cell transplant clinic, or as an inpatient.
What is being studied AICollects and stores blood, tissue, and body-fluid samples for future laboratory research.
Trials that may include large granular lymphocytic leukemia (2)
ClinicalTrials.gov returned these when we searched for this condition, but we could not confirm from the registry records that they are intended for people with it. Check each trial’s eligibility criteria, and ask the study team if you are unsure.
Who can join AIPeople with newly diagnosed Epstein‑Barr virus–positive T/NK‑cell lymphoproliferative diseases, including extranodal NK/T‑cell lymphoma, aggressive NK‑cell leukemia, systemic chronic active EBV (T/NK), and EBV‑positive nodal T/NK‑cell lymphoma.
What is being studied AICollects clinical data and blood/tissue samples to study outcomes and biomarkers in EBV-positive T/NK-cell diseases.